Long-term Mortality After 5-Year Multifactorial Primary Prevention of Cardiovascular Diseases in Middle-aged Men

JAMA: The Journal of the American Medical Association

Volumn 266, Issue 9, 1991, Pages 1225-1229

  Strandberg, Timo E ^a   Salomaa, Veikko V ^b   Naukkarinen, Vesa A ^c   Vanhanen, Hannu T ^a   Sarna, Seppo J ^a   Miettinen, Tatu A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c JORVI HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; FINLAND; FOLLOW-UP STUDIES; HUMAN; MALE; MIDDLE AGE; ODDS RATIO; RISK FACTORS; SUPPORT, NON-U.S. GOV'T;

EID: 0025741778     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1991.03470090059032     Document Type: Article

References (39)

1. Wilhelmson L, Berglund G, Elmfeldt D, et al. The multifactorial primary prevention trial in Göteborg, Sweden. Eur Heart J. 1986;7:279-288.
2. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA. 1982;248:1465-1477.
3. WHO European Collaborative Group. European Collaborative Trial of Multifactorial Prevention of Coronary Heart Disease: final report on the 6year results. Lancet. 1986;1:869-872.
4. Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo study group of a randomised trial in healthy men. Lancet. 1981;2:1303-1310.
5. Rose G, Tunstall-Pedoe HD, Heller RF. UK Heart Disease Prevention Project: incidence and mortality results. Lancet. 1983;1:1062-1066.
6. Miettinen TA, Huttunen JK, Naukkarinen V, et al. Multifactorial primary prevention of cardiovascular diseases in middle-aged men. JAMA. 1985;254:2097-2102.
7. Naukkarinen VA, Strandberg TE, Vanhanen HT, et al. Mortality rates after multifactorial primary prevention of cardiovascular diseases. Ann Med. 1989;21:441-446.
8. Naukkarinen V. The Feasibility of Administering Preventive Treatment for Coronary Heart Disease to Middle-aged Men. Helsinki, Finland: University of Helsinki; 1981. Thesis.
9. Keys A, Aravanis C, Blackburn H, et al. Probability of middle-aged men developing coronary heart disease in five years. Circulation. 1972;45:815-828.
10. Sempos C, Cooper R, Kovar MG, McMillen M. Divergence of the recent trends in coronary mortality for the four major race-sex groups in the United States. Am J Public Health. 1988;78:1422-1427.
11. Huang TC, Chen CP, Wefler V, et al. A stable reagent for Liebermann Burchard reaction: application to rapid serum cholesterol determination. Anal Chem. 1961;33:1405-1407.
12. Dixon WJ. BMDP Statistical Software Manual. Berkeley: University of California Press; 1988.
13. Confidence Interval Analysis (CIA): Microcomputer Program Manual and Disk. London, England: British Medical Journal; 1989.
14. Cox DR. Some procedures connected with the logistic qualitative response curve. In: David FN, ed. Research Papers in Statistics. New York, NY: John Wiley & Sons Inc; 1966:55.
15. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
16. Canner PL, Berge KG, Wenger NK, et al. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
17. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
18. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.
19. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990;301:309-314.
20. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation. 1990;82:1916-1924.
21. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
22. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reduction in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
23. The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial: findings related to a priori hypotheses of the trial. JAMA. 1990;263:1795-1801.
24. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
25. Tall AR. Plasma high density lipoproteins: metabolism and relationship to atherogenesis. J Clin Invest. 1990;86:379-384.
26. Naukkarinen V, Strandberg T, Vanhanen H, Miettinen TA. Probucol-induced electrocardiographic changes in a five-year primary prevention of vascular diseases. Curr Ther Res. 1989;45:232-237.
27. Strandberg TE, Salomaa V, Vanhanen H, Naukkarinen V, Sarna S, Miettinen TA. Longterm effects of probucol and beta-blocker treatment in a primary prevention trial of coronary heart disease. Eur Heart J. 1989;10:217.
28. Helgeland A. Treatment of mild hypertension: a five-year controlled drug trial: the Oslo study. Am J Med. 1980;69:725-732.
29. Vanhanen H. Effects of Long-term Multifactorial Treatment of Coronary Heart Disease on Serum Lipids, Especially on HDL-Cholesterol. Helsinki, Finland: University of Helsinki; 1986. Thesis.
30. Salomaa V. Long-term Effect of Primary Prevention Measures of Coronary Heart Disease on the Risk Factor Levels in Middle-aged Men. Helsinki, Finland: University of Helsinki; 1988. Thesis.
31. Cruikshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1:581-584.
32. Middeke M, Richter WO, Schwandt P, Beck B, Holzgreve H. Normalization of lipid metabolism after withdrawal from antihypertensive long-term therapy with beta blockers and diuretics. Arteriosclerosis. 1990;10:145-147.
33. Struthers AD, Murphy MB, Dollery CT. Glucose tolerance during antihypertensive therapy in patients with diabetes mellitus. Hypertension. 1985;7(suppl II):II-95-II-101.
34. Committee of Principal Investigators. WHO Cooperative Trial on Primary Prevention of Ischaemic Heart Disease With Clofibrate to Lower Serum Cholesterol: final mortality follow-up. Lancet. 1984;2:600-604.
35. Physicians of the Newcastle Upon Tyne Region. Trial of clofibrate in the treatment of ischaemic heart disease. BMJ. 1971;4:767-775.
36. Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. BMJ. 1971;4:775-784.
37. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
38. Pyörälä K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart risk factor: relationship to other risk factors and predictive value during 9½-year follow-up of the Helsinki Policeman Study population. Acta Med Scand. 1985;701(suppl):38-52.
39. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336:129-133.